<DOC>
	<DOCNO>NCT02638207</DOCNO>
	<brief_summary>Study evaluate Efficacy Safety Three Different Dosages NewGam Patients With Chronic Inflammatory Demyelinating Poly ( radiculo ) neuropathy</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Three Different Dosages NewGam Patients With Chronic Inflammatory Demyelinating Poly ( Radiculo ) Neuropathy</brief_title>
	<detailed_description>Prospective , Double-blind , Randomized , Multicenter Phase III Study Evaluating Efficacy Safety Three Different Dosages NewGam Patients With Chronic Inflammatory Demyelinating Poly ( radiculo ) neuropathy ( `` ProCID trial '' )</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<criteria>1 . Patients diagnosis definite probable Chronic inflammatory demyelinate polyneuropathy ( CIDP ) accord European Federation Neurological Societies/Peripheral Nerve Society ( EFNS/PNS ) Guideline 2010 [ van den Bergh et al. , 2010 ] ; include patient Multifocal Acquired Demyelinating Sensory And Motor Neuropathy ( MADSAM ) pure motor Chronic inflammatory demyelinate polyneuropathy ( CIDP ) 2 . Patients currently depend treatment immunoglobulin corticosteroids 3 . Patients active disease , i.e . remission , progressive relapse prior trial start Washout Phase 4 . Weakness least 2 limb 5 . 18 year age old 6 . Adjusted Inflammatory Neuropathy Cause Treatment ( INCAT ) disability score 2 9 ( score 2 come exclusively leg disability ) 7 . Voluntarily give , fully inform write consent obtain patient studyrelated procedure conduct 1 . Unifocal form Chronic inflammatory demyelinate polyneuropathy ( CIDP ) 2 . Pure sensory Chronic inflammatory demyelinate polyneuropathy ( CIDP ) 3 . Multifocal motor neuropathy ( MMN ) conduction block [ van den Bergh et al. , 2010 ] 4 . Patients previously fail immunoglobulin treatment 5 . Treatment immunomodulatory/suppressive agent ( cyclosporin , methotrexate , mitoxantrone , mycophenolate mofetil azathioprine ) six month prior baseline visit 6 . Patients treat rituximab , alemtuzumab , cyclophosphamide , intensive chemotherapeutic regimen , previous lymphoid irradiation stem cell transplantation 12 month prior baseline visit 7 . Respiratory impairment require mechanical ventilation 8 . Myelopathy evidence central nervous system demyelination significant persist neurological deficit stroke , central nervous system ( CNS ) trauma 9 . Clinical evidence peripheral neuropathy another cause 1. connective tissue disease systemic lupus erythematosus ( SLE ) 2 . HIV infection , hepatitis , Lyme disease 3. cancer ( exception basal cell skin cancer ) 4 . IgM paraproteinemia antimyelin associate glycoprotein antibody 10 . Diabetic neuropathy , unless stable HbA1C treat diabetic patient exceed require normal value 11 . Cardiac insufficiency ( New York Heart Association [ NYHA ] III/IV ) , cardiomyopathy , significant cardiac dysrhythmia require treatment , unstable advanced ischemic heart disease 12 . Severe liver disease ( ALAT 3x &gt; normal value ) 13 . Severe kidney disease ( creatinine 1.5x &gt; normal value ) 14 . Hepatitis B , hepatitis C HIV infection 15 . Thromboembolic event : patient history deep vein thrombosis ( DVT ) within last year prior baseline visit pulmonary embolism ever ; patient susceptibility embolism deep vein thrombosis ( DVT ) 16 . Body mass index ( BMI ) â‰¥40 kg/m2 17 . Patients uncompensated hypothyroidism ( abnormally high ThyroidStimulating Hormone [ TSH ] abnormally low Thyroxine [ T4 ] ) know vitamin B12 deficiency patient n't receive adequate substitution therapy 18 . Medical condition whose symptom effect could alter protein catabolism and/or Immunoglobulin G ( IgG ) utilization ( e.g . proteinlosing enteropathy , nephrotic syndrome ) 19 . Known Immunoglobulin A ( IgA ) deficiency antibody Immunoglobulin A ( IgA ) 20 . History hypersensitivity , anaphylaxis severe systemic response immunoglobulin , blood plasma derive product , component NewGam 21 . Known blood hyperviscosity , hypercoagulable state 22 . Use blood plasmaderived product within three month prior Visit 2 23 . Patients past present history drug abuse alcohol abuse within precede five year prior baseline visit 24 . Patients unable unwilling understand comply study protocol 25 . Participation another interventional clinical study investigational medicinal product ( IMP ) treatment currently three month prior Visit 2 26 . Women breast feeding , pregnant , plan become pregnant , unwilling use effective birth control method ( implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) , sexual abstinence vasectomize partner ) study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Chronic Inflammatory Demyelinating Poly Neuropathy ( CIDP )</keyword>
</DOC>